Amgen Stock Forecast: Pipeline Wins Strengthen Growth Story as MariTide Phase 3 Advances
Amgen Stock Forecast: Pipeline Wins Strengthen Growth Story as MariTide Phase 3 Advances TradingKey
Covered in this story
Analyst targets on Amgen
- Truist Securities: $413 → $380 by Oct 2027 · Hold via Investing.com Canada
- Cantor Fitzgerald: $403 → $400 by Oct 2027 · Neutral via Investing.com
- Scotiabank: $403 → $500 by Oct 2027 via AD HOC NEWS
Published targets verified against independent reporting and tracked to their dates. Not recommendations from Dalsna Finance.
Call it yourself
No member calls on $AMGN yet. A scorecard is a price target with a date and the working behind it — tracked, settled and scored in public.
Make the first call on Amgen →Dalsna Finance is currently tracking 48 stories mentioning Amgen, the earliest published 14 Jul 2026.
Summary aggregated from TradingKey's public RSS feed. The full reporting belongs to TradingKey — please read it on their site.